Corosolic acid enhances 5-fluorouracil-induced apoptosis against SNU-620 human gastric carcinoma cells by inhibition of mammalian target of rapamycin

Molecular Medicine Reports

Volumn 12, Issue 3, 2015, Pages 4782-4788

  Lee, Hyun Su ^a   Park, Jun Beom ^a   Lee, Myung Sun ^a   Cha, Eun Young ^a   Kim, Ji Yeon ^a   Sul, Ji Young ^a,b  

^a Chungnam National University College of Medicine   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

5 Fluorouracil; Corosolic acid; Gastric cancer; Mammalian target of rapamycin

Indexed keywords

ANTINEOPLASTIC AGENT; BIM PROTEIN; CASPASE 3; COROSOLIC ACID; CYTOCHROME C; FLUOROURACIL; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; UNCLASSIFIED DRUG; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRITERPENE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; METABOLISM; STOMACH TUMOR; TUMOR CELL LINE;

MAMMALIA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FLUOROURACIL; HUMANS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES; TRITERPENES;

EID: 84935461747     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3982     Document Type: Article

References (38)

1. Shigematsu H, Yoshida K, Sanada Y, Osada S, Takahashi T, Wada Y, Konishi K, Okada M and Fukushima M: Rapamycin enhances chemotherapy-induced cytotoxicity by inhibiting the expressions of TS and ERK in gastric cancer cells. Int J Cancer 126:2716-2725, 2010.
2. Ohtsu A: Chemotherapy for metastatic gastric cancer: Past, present and future. J Gastroenterol 43:256-264, 2008.
3. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, et al; V-325 Study Group: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 Study Group. J Clin Oncol 25:3205-3209, 2007
4. Lee KH, Hur HS, Im SA, Lee J, Kim HP, Yoon YK, Han SW, Song SH, Oh DY, Kim TY, et al: RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. Cancer Lett 299:22-28, 2010.
5. Benson AB III: New approaches to the adjuvant therapy of colon cancer. Oncologist 11:973-980, 2006.
6. Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338, 2003.
7. Sasaki E, Tominaga K, Kuwamura H, Watanabe T, Fujiwara Y, Oshitani N, Higuchi K and Arakawa T: Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2, 4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: Possible role of a dihydropyrimidine dehydrogenase-independent mechanism. J Gastroenterol 42:816-822, 2007
8. Wang J, Liu W, Zhao Q, Qi Q, Lu N, Yang Y, Nei FF, Rong JJ, You QD and Guo QL: Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology 256:135-140, 2009
9. Parker WB and Cheng YC: Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48:381-395, 1990.
10. Peters GJ, Van Der Wilt CL, Van Triest B, Codacci-Pisanelli G, Johnston PG, Van Groeningen CJ and Pinedo HM: Thymidylate synthase and drug resistance. Eur J Cancer 31:1299-1305, 1995.
11. Papamichael D: The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: Current status. Stem Cells 18:166-175, 2000.
12. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993.
13. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000.
14. Chon HJ, Rha SY, Im CK, Kim C, Hong MH, Kim HR, An JR, Noh SH, Chung HC and Jeung HC: Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Res Treat 41:196-204, 2009.
15. Choi EJ and Kim GH: 5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells. Oncol Rep 22:1533-1537, 2009.
16. Hou W, Li Y, Zhang Q, Wei X, Peng A, Chen L and Wei Y: Triterpene acids isolated from Lagerstroemia speciosa leaves as alpha-glucosidase inhibitors. Phytother Res 23:614-618, 2009.
17. Kim E, Sy-Cordero A, Graf TN, Brantley SJ, Paine MF and Oberlies NH: Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes. Planta Med 77:265-270, 2011.
18. Lee MS, Lee CM, Cha EY, Thuong PT, Bae K, Song IS, Noh SM and Sul JY: Activation of AMP-activated protein kinase on human gastric cancer cells by apoptosis induced by corosolic acid isolated from Weigela subsessilis. Phytother Res 24:1857-1861, 2010.
19. Stohs SJ, Miller H and Kaats GR: A review of the efficacy and safety of banaba (Lagerstroemia speciosa L.) and corosolic acid. Phytother Res 26:317-324, 2012.
20. Miura T, Ueda N, Yamada K, Fukushima M, Ishida T, Kaneko T, Matsuyama F and Seino Y: Antidiabetic effects of corosolic acid in KK-Ay diabetic mice. Biol Pharm Bull 29:585-587, 2006.
21. Fukushima M, Matsuyama F, Ueda N, Egawa K, Takemoto J, Kajimoto Y, Yonaha N, Miura T, Kaneko T, Nishi Y, et al: Effect of corosolic acid on postchallenge plasma glucose levels. Diabetes Res Clin Pract 73:174-177, 2006.
22. Banno N, Akihisa T, Tokuda H, Yasukawa K, Higashihara H, Ukiya M, Watanabe K, Kimura Y, Hasegawa J and Nishino H: Triterpene acids from the leaves of Perilla frutescens and their anti-inflammatory and antitumor-promoting effects. Biosci Biotechnol Biochem 68:85-90, 2004.
23. Zong W and Zhao G: Corosolic acid isolation from the leaves of Eriobotrta japonica showing the effects on carbohydrate metabolism and differentiation of 3T3-L1 adipocytes. Asia Pac J Clin Nutr 16:346-352, 2007.
24. Chen H, Yang J, Zhang Q, Chen LH and Wang Q: Corosolic acid ameliorates atherosclerosis in apolipoprotein E-deficient mice by regulating the nuclear factor-κB signaling pathway and inhibiting monocyte chemoattractant protein-1 expression. Circ J 76:995-1003, 2012.
25. Xu Y, Ge R, Du J, Xin H, Yi T, Sheng J, Wang Y and Ling C: Corosolic acid induces apoptosis through mitochondrial pathway and caspase activation in human cervix adenocarcinoma HeLa cells. Cancer Lett 284:229-237, 2009.
26. Cai X, Zhang H, Tong D, Tan Z, Han D, Ji F and Hu W: Corosolic acid triggers mitochondria and caspase-dependent apoptotic cell death in osteosarcoma MG-63 cells. Phytother Res 25:1354-1361, 2011.
27. Lee MS, Cha EY, Thuong PT, Kim JY, Ahn MS and Sul JY: Down-regulation of human epidermal growth factor receptor 2/neu oncogene by corosolic acid induces cell cycle arrest and apoptosis in NCI-N87 human gastric cancer cells. Biol Pharm Bull 33:931-937, 2010.
28. Fujiwara Y, Komohara Y, Ikeda T and Takeya M: Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B in tumor cells and tumor-associated macrophages. Cancer Sci 102:206-211, 2011.
29. Horlad H, Fujiwara Y, Takemura K, Ohnishi K, Ikeda T, Tsukamoto H, Mizuta H, Nishimura Y, Takeya M and Komohara Y: Corosolic acid impairs tumor development and lung metastasis by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells. Mol Nutr Food Res 57:1046-1054, 2013.
30. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, et al: Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120:1803-1810, 2007.
31. Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T, Ohira M and Hirakawa K: Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 100:2402-2410, 2009.
32. Jackson C, Cunningham D and Oliveira J; ESMO Guidelines Working Group: Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):34-36, 2009.
33. Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168, 1997.
34. Lei X, Lv X, Liu M, Yang Z, Ji M, Guo X and Dong W: Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo. Biochem Biophys Res Commun 417:864-868, 2012.
35. Tang D, Lotze MT, Kang R and Zeh HJ: Apoptosis promotes early tumorigenesis. Oncogene 30:1851-1854, 2011.
36. Bjornsti MA and Houghton PJ: The TOR pathway: A target for cancer therapy. Nat Rev Cancer 4:335-348, 2004.
37. Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell 124:471-484, 2006.
38. Tomioka H, Mukohara T, Kataoka Y, Ekyalongo RC, Funakoshi Y, Imai Y, Kiyota N, Fujiwara Y and Minami H: Inhibition of the mTOR/S6 K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. Int J Oncol 41:551-558, 2012.